Pure Global AI
NCT06158945Recruiting

The Role of Endothelin 1 as a Marker of Renal Impairment in Sickle Cell Disease

Sohag UniversityClinicalTrials.govdiagnostic test
Verified
Study focus
Disease/Condition
Sickle Cell Disease
Drug/Device/Intervention
urinary endothelin 1
Study type
Observational
Intervention type
diagnostic test
Sponsor & location
Primary sponsor
Sohag University
Location
Sohag, Egypt
Timeline & enrollment
Phase
N/A
Start date
Oct 24, 2023
End date
Oct 23, 2024
Enrollment
30 participants
Primary outcome

renal affection in sickle cell patients

Summary

Sickle cell disease (SCD) refers to a group of hemoglobinopathies that include mutations in
 the gene encoding the beta subunit of hemoglobin. Within the umbrella of SCD, many subgroups
 exist, namely sickle cell anemia (SCA), hemoglobin SC disease (HbSC), and hemoglobin
 sickle-beta-thalassemia (beta-thalassemia positive or beta-thalassemia negative). Several
 other minor variants within the group of SCDs also, albeit not as common as the varieties
 mentioned above. It is essential to mention the sickle cell trait (HbAS), which carries a
 heterozygous mutation and seldom presents clinical signs or symptoms. Sickle cell anemia is
 the most common form of SCD

ICD-10 classifications
Sickle-cell disordersOther sickle-cell disordersSickle-cell traitSickle-cell anaemia with crisisSickle-cell anaemia without crisis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06158945
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06158945 through Pure Global AI's free database. This phase not specified trial is sponsored by Sohag University and is currently Recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.